Azom (aztreonam) is a prescription medicine that may be used to support the management of certain bacterial infections. Healthcare professionals may consider Azom to address infections in a variety of body areas, primarily those caused by susceptible Gram-negative bacteria.

Quick Facts

• Respiratory Support: May be considered for bacterial infections affecting the lungs, such as pneumonia.
• Urinary Tract: May help manage both complicated and uncomplicated urinary tract infections (UTIs).
• Skin and Soft Tissue: May contribute to the resolution of bacterial infections of the skin and underlying tissues.
• Intra-abdominal Care: A therapeutic option for infections within the abdomen, including peritonitis.
• Systemic Infections: May be used in the care plan for bacterial infections that have entered the bloodstream (septicemia).

Azom is also available in an inhaled formulation to help manage respiratory symptoms in patients with cystic fibrosis who are known to have Pseudomonas aeruginosa in the lungs.

Who Can and Cannot Use Azom?

This section outlines the official population eligibility and non-eligibility information based strictly on government regulatory documents for medicines associated with the name, such as Azithromycin and Azomyr (Desloratadine).

Populations That Must Not Use This Medicine (Contraindications)

Contraindication	Basis
Hypersensitivity	Known allergy to the active substance, its drug class (e.g., macrolides for Azithromycin), or any excipient.
Prior Liver Reaction	History of cholestatic jaundice or liver dysfunction previously associated with Azithromycin use.

Populations Requiring Restricted or Conditional Use

Use requires caution or special consideration in individuals with:

• Cardiovascular Conditions: Patients with known QT prolongation or other proarrhythmic conditions (Azithromycin).
• Organ Impairment: Patients with severe hepatic impairment or severe renal impairment.
• Myasthenia Gravis: Azithromycin use may exacerbate muscle weakness.
• Hereditary Conditions: Certain formulations containing lactose are contraindicated for those with rare hereditary problems like galactose intolerance.

Age and Reproductive Eligibility

Population Group	Eligibility Status
Infants/Children	Use not established for infants under specific minimum ages (e.g., typically under 6 months for oral Azithromycin or under 1 year for Azomyr syrup).
Pregnancy/Lactation	Not generally recommended; use should be avoided or approached with caution, as safety is not fully established.

The official interaction profile for Azom (Azithromycin) is defined by restrictions and required monitoring for co-administered substances.

Co-administration with Ergot Alkaloids (e.g., ergotamine, dihydroergotamine) is formally classified as a contraindication in regulatory labeling due to the theoretical risk of acute ergotism. A key pharmacodynamic risk is the documented additive QT prolongation when Azom is combined with other medicinal products known to prolong the QT interval, which necessitates caution.

Pharmacokinetic interactions are documented, notably the drug's effect on cellular transport. Azom may lead to increased serum concentrations of P-glycoprotein substrates such as Digoxin and Colchicine. Furthermore, the co-administration of Nelfinavir is officially stated to increase Azithromycin's own systemic exposure ( AUC and C max). For oral anticoagulants like Warfarin, regulatory documents mandate monitoring of Prothrombin Time (INR) due to reported potentiation of anticoagulation.

Unlike some other macrolides, Azom is officially reported as not having a significant interaction with the hepatic CYP3A4 enzyme system. Mandatory timing rules exist: Aluminum- or Magnesium-containing Antacids must not be taken simultaneously with Azom, as this reduces the peak plasma concentration. Separately, Azithromycin capsules and suspension must be taken on an empty stomach. Finally, systemic exposure to Azithromycin is significantly increased in patients with severe renal impairment, which is a key population-specific consideration.

Direct Blockade of Bacterial Protein Synthesis

Azithromycin exerts its primary action by selectively binding to the 23S ribosomal RNA within the bacterial 50S ribosomal subunit. This precise molecular attachment physically blocks the nascent peptide exit tunnel, which is essential for the bacteria to build new proteins and replicate. This process inhibits the growth and proliferation of susceptible microorganisms, resulting in a profound bacteriostatic effect which decreases the potential for microbial growth.

---

Modulation of Host Inflammatory Responses

A distinct, secondary action of Azithromycin is the modulation of the host's immune system. The molecule accumulates inside immune cells, where it interferes with intracellular signaling pathways (e.g., NF-κB and cPLA2), leading to a reduction in the release of powerful pro-inflammatory mediators and chemokines. This mechanism contributes to the attenuation of excessive inflammation by reducing the concentration of inflammatory mediators, which alters the physiological response in the affected tissue.

---

Mechanistic Constraints and Specificity

The drug's mechanism is highly selective for prokaryotic ribosomes, establishing mechanistic specificity for prokaryotic ribosomes over eukaryotic ribosomes. However, the effectiveness of this action is constrained by bacterial countermeasures, such as enzymatic methylation of the 23S rRNA binding site or the activation of dedicated efflux pumps that actively expel the drug. When these resistance mechanisms are present, the drug's access to its primary molecular target is compromised, reducing the functional scope of its molecular action.

How Azom (Azithromycin) is Used: Dosing and Administration

---

Approved Routes and Forms

Azithromycin is approved for oral administration (tablets, capsules, and suspension) and intravenous (IV) administration (powder for injection). The choice of route depends on the patient's condition and the type of infection being treated.

---

Standard Adult Dosing and Treatment Patterns

Dosing, frequency, and duration are based on the specific indication. Azithromycin is typically administered as a single dose once daily.

Indication (Example)	Standard Labeled Regimen	Total Duration Pattern
Most Infections	500 mg on Day 1, then 250 mg daily	5-day course (Total 1,500 mg)
Uncomplicated Genital	Single dose of 1,000 mg (1 gram)	Single-dose therapy
IV Therapy	500 mg once daily	2 days (followed by oral step-down)

---

Key Administration Conditions

• With or Without Food: Azithromycin tablets and standard oral suspension generally may be taken with or without food. However, the extended-release suspension is taken on an empty stomach (at least 1 hour before or 2 hours after a meal).
• Antacids: Antacids containing aluminum or magnesium may interfere with the absorption of Azithromycin; doses are typically separated by at least 1 to 2 hours.
• IV Administration: The IV formulation is administered as a slow, diluted intravenous infusion over 1 to 3 hours and is not intended for rapid injection.

---

Population-Specific Use

Dose adjustments are generally not required for older adults or patients with mild to moderate kidney or liver impairment. Pediatric dosing is determined by weight.

Research Evidence / Overview of Studies for Azom

The research evidence for Azom (azithromycin) was built upon data from controlled clinical trials and scientific reviews conducted under the supervision of global health authorities. This summary focuses on the structure of that evidence—what researchers studied, what findings were observed, and what questions remain unanswered—without offering advice or making claims about individual outcomes.

---

Evidence for Use in Acute Respiratory Infections (Pneumonia and COPD Exacerbations)

The core evidence structure for Azom in acute respiratory conditions, such as Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbations of Chronic Obstructive Pulmonary Disease (ABECB), was built upon data from Randomized Controlled Trials (RCTs) and comparative studies. Researchers studied diverse populations, including adults and children 6 months of age. These trials primarily examined outcomes related to symptom evolution. Key measurements tracked included endpoints for clinical response (assessing changes in fever and respiratory discomfort) and the rate of microbiological status changes (changes in targeted bacteria).

---

Evidence for Use in Specialized and Non-Respiratory Infections (Chlamydia)

For certain non-respiratory infections, such as uncomplicated infections caused by Chlamydia trachomatis, studies primarily used RCTs and prospective cohort designs to compare Azom's single-dose regimen against multi-day alternative treatments. The key outcome examined in these research scenarios was the achievement of microbiological clearance status, determined by laboratory testing at a predefined follow-up visit. Data for infections at all non-genital sites (such as rectal or pharyngeal) remain insufficient.

---

Evidence for Long-Term Management of Specific Chronic Lung Conditions (Cystic Fibrosis)

Azom was studied for chronic use, primarily in conditions involving functional limitations, such as Cystic Fibrosis (CF), where patients have persistent Pseudomonas aeruginosa lung colonization. These long-term RCTs, often lasting six months or more, monitored functional outcomes reflecting daily functioning. Measured outcomes included changes in pulmonary function tests (e.g., FEV1) and the frequency of episodic or acute changes. Follow-up durations were limited in terms of characterizing very long-term effects beyond the initial trial period.

---

Research Gaps and Areas of Uncertainty

Authoritative scientific sources indicate several areas where the research evidence is limited or ongoing. Antimicrobial resistance is a persistent concern, and research continues to monitor how Azom’s use was associated with an increase in resistant bacteria observed in some studies. Subgroup findings are uncertain in many cases. Ultimately, research provides context about group patterns but does not determine whether an individual with unique health factors will respond similarly, meaning clinical evidence quality varies across studies.

Common questions about Azom (FAQ)

Q: What is Azom and how does it work?

A: Azom is the brand name for the drug azithromycin, which belongs to a class of antibiotics called macrolides. It works by stopping the growth of bacteria. Specifically, it binds to a part of the bacteria's ribosome (the 50S subunit), which prevents the bacteria from making essential proteins needed for growth and replication. This makes Azom effective against a wide range of bacterial infections.

Q: What types of infections does Azom treat?

A: Azom is commonly prescribed to treat various bacterial infections, including:

• Respiratory tract infections, such as community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, and sinusitis.
• Skin and soft tissue infections.
• Sexually transmitted diseases caused by susceptible organisms, such as Chlamydia trachomatis.
• Ear infections (otitis media).

It is important to note that Azom is not effective against viral infections like the common cold or flu.

Q: How should I take Azom?

A: Azom is typically taken by mouth as a tablet, capsule, or liquid suspension. The way you take it depends on the specific product and the infection being treated. Always follow your doctor's instructions exactly regarding the dose and duration of treatment. Some forms of Azom can be taken with or without food, while others may be recommended to be taken on an empty stomach.

Q: What are the common side effects of Azom?

A: Common side effects of Azom are usually mild and temporary. They can include:

• Nausea, vomiting, and diarrhea.
• Abdominal pain.
• Headache.

If these side effects are severe or persistent, you should contact your healthcare provider. Serious side effects are rare but can include severe allergic reactions or liver problems, and require immediate medical attention.

Q: Can Azom interact with other medications?

A: Yes, Azom can interact with several other medications, which may change how Azom or the other medicine works. Key medications that may interact include:

• Antacids containing aluminum or magnesium (these should be taken at least 2 hours apart from Azom).
• Warfarin (a blood thinner).
• Certain heart rhythm medications (such as amiodarone, quinidine, or dofetilide).
• Nelfinavir (an HIV medication).

Always provide your healthcare provider with a complete list of all prescription, over-the-counter drugs, and herbal supplements you are taking before starting Azom.

How to Store and Dispose of Azom?

Storage Requirements

Azom must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication should be kept in its original package and protected from excessive heat. Storage areas must comply with general regulatory guidelines requiring them to be clean and dry. Avoid any conditions that could compromise the product's integrity.

Disposal Instructions

When Azom is expired, unused, or no longer needed, it must be disposed of properly to prevent misuse and environmental contamination. The best disposal option is a formal drug take-back program, such as those offered by pharmacies or law enforcement.

If a take-back option is unavailable, and the drug is not on the U.S. Food and Drug Administration's (FDA) flush list, you can discard it in the household trash. To do this safely, remove the medication from its container, mix it with an unappealing substance like dirt or used coffee grounds, place the mixture in a sealed bag or container, and dispose of it in the trash. Never flush medication down the toilet or pour it down the sink unless specifically instructed by the product's official label.